Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
Mohan M, Szabo A, Patwari A, Esselmann J, Patel T, Bachu R, Rein LE, Janardan A, Bhatlapenumarthi V, Annyapu E, Skoog C, Goff A, Hadidi SA, Radhakrishnan SV, Thanendrarajan S, Zangari M, Shah N, van Rhee F, Dhakal B, Hamadani M, D'Souza A, Schinke C. Mohan M, et al. Among authors: radhakrishnan sv. Bone Marrow Transplant. 2024 May;59(5):647-652. doi: 10.1038/s41409-024-02233-2. Epub 2024 Feb 15. Bone Marrow Transplant. 2024. PMID: 38361116
Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study.
Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A; N3C consortium. Mohan M, et al. Among authors: radhakrishnan sv. Bone Marrow Transplant. 2024 Jan;59(1):121-124. doi: 10.1038/s41409-023-02096-z. Epub 2023 Oct 6. Bone Marrow Transplant. 2024. PMID: 37803198 No abstract available.
Restricting CAR T Cell Trafficking Expands Targetable Antigen Space.
Morales EA, Dietze KA, Baker JM, Wang A, Avila SV, Iglesias F, Radhakrishnan SV, Mause EV, Olson ML, Sun W, Rosati E, Chidester SL, Iraguha T, Fan X, Atanackovic D, Luetkens T. Morales EA, et al. Among authors: radhakrishnan sv. bioRxiv [Preprint]. 2024 Feb 11:2024.02.08.579002. doi: 10.1101/2024.02.08.579002. bioRxiv. 2024. PMID: 38370665 Free PMC article. Preprint.
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. Hammons L, et al. Among authors: radhakrishnan sv. Haematologica. 2024 Mar 1;109(3):906-914. doi: 10.3324/haematol.2023.283590. Haematologica. 2024. PMID: 37646658 Free PMC article.
Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity.
Vander Mause ER, Baker JM, Dietze KA, Radhakrishnan SV, Iraguha T, Omili D, Davis P, Chidester SL, Modzelewska K, Panse J, Marvin JE, Olson ML, Steinbach M, Ng DP, Lim CS, Atanackovic D, Luetkens T. Vander Mause ER, et al. Among authors: radhakrishnan sv. Sci Transl Med. 2023 Jul 19;15(705):eadd7900. doi: 10.1126/scitranslmed.add7900. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467316
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, Thalambedu N, Khan F, Sethi J, Janardan A, Radhakrishnan SV, Thanendrarajan S, Schinke C, Dhakal B, Janz S, Chhabra S, D'Souza A, Zangari M, van Rhee F, Mohan M. Al Hadidi S, et al. Among authors: radhakrishnan sv. Bone Marrow Transplant. 2023 Apr;58(4):443-445. doi: 10.1038/s41409-022-01905-1. Epub 2022 Dec 22. Bone Marrow Transplant. 2023. PMID: 36550200 No abstract available.
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Mohan M, Rein LE, Thalambedu N, Ogunsesan Y, Hussain M, Sethi J, Khan F, Gundarlapalli S, Yarlagadda L, Dhakal B, Price M, Shirey M, Warner D, Thanendrarajan S, Janz S, Radhakrishnan SV, Al Hadidi S, Szabo A, D'Souza A, Zangari M, van Rhee F, Chhabra S, Schinke C. Mohan M, et al. Among authors: radhakrishnan sv. Am J Hematol. 2022 Dec;97(12):E451-E453. doi: 10.1002/ajh.26728. Epub 2022 Sep 24. Am J Hematol. 2022. PMID: 36097868 Free article. No abstract available.
29 results